Table 1.
Chemotherapeutic agents associated with acute coronary syndrome. ACS: acute coronary syndrome; CAD: coronary artery disease.
| Incidence | Presentations | Cancer Therapy | |
|---|---|---|---|
| Antimetabolites | |||
| 5-Fluorouracil [7] | 0.1–18% | Angina, Vasospasm, ACS | Colorectal, pancreas, gastric breast |
| Alkylating agents | |||
| Cisplatin [8] | 0.2–12% | Angina, coronary thrombosis, ACS, progression of CAD | Ovarian, Testicular, Bladder, squamous cell of head and neck, mesothelioma |
| Antitumor antibiotics | |||
| Bleomycine [9] | <2% | Angina, vasospasm, ACS | Testicular, cervix, Hodgkin’s and non-Hodgkins lymphoma |
| Anti-microtubule agents | |||
| Vinblastine [9] | <5% | Angina, ACS | Testicular, lymphoma, breast cancer |
| Monoclonal antibodies | |||
| Rituximab [16] | <1% | Vasospasm, ACS, Takotsubo cardiomyopathy | Non-Hodgkin’s lymphoma, ChronicLymphocytic Leukemia |
| Tyrosine kinase inhibitors | |||
| Sorafenib [14] | 1% | Angina, ACS | Liver, renal cell, thyroid cancer |
| Sunitinib [12,13] | 5–8% | ACS, Takotsubo cardiomyopathy, progression of CAD | Pancreas, renal cell, gastrointestinal stromal tumor |
| Nilotinib [15] | 8–12% | ACS, progression of CAD, peripheral artery disease | Chronic myeloid Leukemia |
| Hormone therapy | |||
| Aromatase inhibitors (anastrozole) [19] | 2% | Angina, ACS | Breast cancer |
| Anti-androgens (bicalbutide) [17] | 1–33% | ACS, progression of CAD | Prostate cancer |
| Gonadotropin-releasing hormone agonist (goserelin) [18] | 1–2% | Angina, ACS | Prostate cancer |
| Gonadothropin-releasing hormone antagonist (degarelix) [18] | <1% | ACS | Prostate cancer |